This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Investigating Intellia’s CRISPR therapy NTLA-2002 in development for the treatment of swelling attacks in hereditary angioedema (HAE).

Ticker(s): NTLA

Who's the expert?

Institution: University of Tennessee

  • Associate Professor and Director of Allergy & Immunology training at the University of Tennessee.
  • Manages 3 patients with Hereditary angioedema.
  • Research focuses on food allergy, anaphylaxis, primary immune deficiency, and drug allergy.

Interview Goal
This call will focus on the recent results from the phase 1 study of Intellia Therapeutics' CRISPR therapy NTLA-2002 in patients with hereditary angioedema.

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.


*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.